7205-46-1

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is used as an intermediate in the synthesis of various pharmaceutical compounds and biologically active molecules, contributing to the development of new drugs with potential therapeutic applications.
Used in Anticancer Applications:
6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is used as an anticancer agent, exhibiting potential biological activities that can be harnessed for the development of new cancer treatments.
Used in Antiviral Applications:
6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is used as an antiviral agent, with its potential biological activities being explored for the development of new antiviral therapies.
Used in Medicinal Chemistry and Drug Discovery:
6-Chloro-1-Methyl-1H-iMidazo[4,5-c]pyridine is used as an important target in medicinal chemistry and drug discovery, due to its heterocyclic nature and potential biological activities, making it a promising candidate for further research and development in the pharmaceutical industry.

Upstream product

• 64-18-6 formic acid 
• 87034-76-2 6-chloro-N⁴-methylpyridine-3,4-diamine 
• 607373-83-1 2-chloro-4-methoxy-5-nitro-pyridine 
• 1449506-71-1 (2-chloro-5-nitro-pyridin-4-yl)-methyl-amine 
• 149-73-5 trimethyl orthoformate 
• 13091-23-1 4-chloro-3-nitropyridine 
• 850663-54-6 4-chloro-2-hydroxy-5-nitropyridine 
• 4487-56-3 2,4-dichloro-5-nitropyridine 

Downstream Products

• 1449515-01-8 2-[3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]propionitrile 
• 1449515-02-9 (2-difluoromethoxy-4-methylphenyl)-(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amine 
• 1449515-03-0 2-[3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]-3-oxopropionitrile 
• 1449515-06-3 1-[3-ethyl-4-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl]cyclopropane carbonitrile 
• 1449515-21-2 (2-ethyl-phenyl)-(1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)-amine 
• 1449515-71-2 N-(2-ethyl-4-(pyrimidin-5-yl)phenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449514-89-9 N-(2-ethyl-4-fluorophenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449514-90-2 N-(4-(4-methoxybenzyloxy)-2-methylphenyl)-1-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449514-92-4 4-(4-methoxybenzyl)-7-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1449514-93-5 4-ethyl-N,N-dimethyl-3-(1-methyl-1H-imidazo[ 4,5-c]pyridin-6-ylamino)benzamide 
• 1449514-94-6 (4-ethyl-3-(1-methyl-1H-imidazo[4,5-c]pyridin-6-ylamino)phenyl)methanol 
• 1449668-98-7 C₁₇H₁₈N₄O₂ 
• 1449506-73-3 tert-butyl 4-(3-ethyl-4-((1-methyl-1H-imidazo[4,5-c]pyridin-6-yl)amino)phenyl)-5,6-dihydropyridine-1(2H)-carboxylate 
• 1449664-52-1 N-(2-chloro henyl)-N,1-dimethyl-1H-imidazo[4,5-c]pyridin-6-amine 

Relevant academic research and scientific papers

AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS

The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators

The present invention relates to imidazo[5,4-c]pyridine or pyrrolo[3,2-c]pyridine compounds and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds, as well as pharmaceutical compositions containing at least one of these pyridine-based bicyclic compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said pyridine-based bicyclic compounds are assumed to be modulators of the GRK5 protein, thereby regulating the expression and/or release of insulin and are useful for the treatment or prophylaxis of a metabolic disease and in particular for the treatment and prophylaxis of diabetes, obesity and impaired adipogenesis.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.